The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

Abstract Background Synapse damage and loss are fundamental to the pathophysiology of Alzheimer’s disease (AD) and lead to reduced cognitive function. The goal of this review is to address the challenges of forging new clinical development approaches for AD therapeutics that can demonstrate reductio...

Full description

Bibliographic Details
Main Authors: Martí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John E. Harrison, Lon S. Schneider, Phillip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo, Susan M. Catalano, the Synaptic Health Endpoints Working Group
Format: Article
Language:English
Published: BMC 2020-03-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease
Synapse
Biomarker
Cerebrospinal fluid
Positron emission tomography
Electroencephalography
Online Access:http://link.springer.com/article/10.1186/s13195-020-00588-4

Internet

http://link.springer.com/article/10.1186/s13195-020-00588-4

Similar Items